- Home
- INBS vs MYNZ Comparison
INBS vs MYNZ Comparison
Compare INBS & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBS | MYNZ |
|---|---|---|
| Founded | 2016 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.4M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | INBS | MYNZ |
|---|---|---|
| Price | $4.45 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 74.9K | ★ 274.2K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.65 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,980,484.00 | N/A |
| Revenue This Year | $778.48 | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.55 |
| 52 Week High | $24.90 | $5.69 |
Technical Indicators
Market Signals| Indicator | INBS | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 35.91 | 40.78 |
| Support Level | $4.03 | $0.60 |
| Resistance Level | $7.25 | $1.71 |
| Average True Range (ATR) | 0.56 | 0.11 |
| MACD | -0.07 | 0.00 |
| Stochastic Oscillator | 28.37 | 44.48 |
Price Performance
Historical ComparisonAbout INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.